Matthew Hemington

Cooley advised Intersect ENT, a commercial drug delivery company, on its agreement to acquire Fiagon, a developer of clinical navigation systems. Partner Matt Hemington led the Cooley team.

Cooley advised Si-Bone, a developer of surgical instruments, in its $92.5 million follow-on offering.

Cooley advised Intersect ENT on its $65 million convertible notes financing. Intersect ENT is a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions.

Cooley advised 1Life Healthcare, a membership-based primary care platform with seamless digital health and inviting in-office care, in its $257.3 million follow-on offering.

Cooley advised Si-Bone on its $124.2 million initial public offering of 8,280,000 shares of common stock. Matthew Hemington and John McKenna led the Cooley team advising Si-Bone.

Morgan Stanley and Merrill Lynch acted as the lead book-running managers for the offering. Canaccord Genuity and JMP Securities acted as co-managers for the offering.

Si-Bone is a medical device company that has pioneered a treatment for sacroiliac joint dysfunction that often causes severe lower back pain. The company’s shares now trade on the Nasdaq Global Market under the symbol “SIBN.”